Black Diamond Therapeutics Q3 2026 Net Loss Widens 18% Year Over Year to $10 Million

• Black Diamond Therapeutics’ third-quarter 2026 net loss widened 18% year over year to $10 million.
• General and administrative expenses rose 46% year over year to $5.1 million, due to higher IP-related costs and non-income tax expense.
• Cash, cash equivalents, and investments totaled $102 million at September 30, 2026, with expected funding into the second half of 2028.
• Silevertinib’s Phase 2 trial showed an 86% CNS response rate in evaluable patients with untreated brain metastases.
• Following FDA feedback, a Phase 3 silevertinib trial could begin in second-quarter 2027, with a potential accelerated approval pathway.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Black Diamond Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001701541-26-000030), on November 10, 2026, and is solely responsible for the information contained therein.